Finally, in patient-derived subcutaneous melanoma xenografts engrafted with autologous immune cells from the same patient, we observed significantly longer survival of mice receiving CSPG4 IgE, compared to controls treated with the patient’s immune cells alone. This evidence concerns the gene CSPG4 and melanoma.